The Australasian Resuscitation In Sepsis Evaluation: Fluids or vasopressors in emergency department sepsis (ARISE FLUIDS), a multi-centre observational study describing current practice in Australia and New Zealand.
Ontology highlight
ABSTRACT: OBJECTIVES:To describe haemodynamic resuscitation practices in ED patients with suspected sepsis and hypotension. METHODS:This was a prospective, multicentre, observational study conducted in 70 hospitals in Australia and New Zealand between September 2018 and January 2019. Consecutive adults presenting to the ED during a 30-day period at each site, with suspected sepsis and hypotension (systolic blood pressure?<100?mmHg) despite at least 1000?mL fluid resuscitation, were eligible. Data included baseline demographics, clinical and laboratory variables and intravenous fluid volume administered, vasopressor administration at baseline and 6- and 24-h post-enrolment, time to antimicrobial administration, intensive care admission, organ support and in-hospital mortality. RESULTS:A total of 4477 patients were screened and 591 were included with a mean (standard deviation) age of 62 (19) years, Acute Physiology and Chronic Health Evaluation II score 15.2 (6.6) and a median (interquartile range) systolic blood pressure of 94?mmHg (87-100). Median time to first intravenous antimicrobials was 77?min (42-148). A vasopressor infusion was commenced within 24?h in 177 (30.2%) patients, with noradrenaline the most frequently used (n = 138, 78%). A median of 2000?mL (1500-3000) of intravenous fluids was administered prior to commencing vasopressors. The total volume of fluid administered from pre-enrolment to 24?h was 4200?mL (3000-5661), with a range from 1000 to 12?200?mL. Two hundred and eighteen patients (37.1%) were admitted to an intensive care unit. Overall in-hospital mortality was 6.2% (95% confidence interval 4.4-8.5%). CONCLUSION:Current resuscitation practice in patients with sepsis and hypotension varies widely and occupies the spectrum between a restricted volume/earlier vasopressor and liberal fluid/later vasopressor strategy.
SUBMITTER: Keijzers G
PROVIDER: S-EPMC7496107 | biostudies-literature | 2020 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA